Hanmi's $200M China plant likely to make branded drugs versus generics

South Korean drug manufacturer Hanmi is building a $200 million manufacturing plant and R&D center in China, though it won't, apparently, be producing generic drugs at the facility.

The company announced earlier this year it would build the plant on a 200,000-square-meter swath of land near Yantai in an economic development zone in the eastern province of Shandong. The facility will be the production site for chemosynthetic and biological drugs as well as various health foods. However, the company known for generics has decided to take a different route and is steering toward branded medicine. It will commit 80% of its R&D toward that end, a top executive of the company said.

“We will embark on an R&D strategy in which we gradually reduce the weight taken up by generics and come out as a company specializing in branded drugs,” Hanmi President Lee Gwan-sun told The Nikkei. The company has been steadily growing its presence in China since starting up business there in 1996.

"Among global pharmaceutical markets, China will probably experience continuously high growth," Lee told the publication. "We're set on leveraging our two decades' worth of experience in China to develop the market.” The majority of the drugs Hanmi has zeroed in on are for obesity, diabetes, autoimmune diseases and cancer.

After seeing its stock soar to astronomical levels after signing licensing deals with large Western pharma companies in 2015, Hanmi’s shares stagnated, and the move into branded drugs is seen as part of Lee’s strategy to reinvigorate revenues.

In its fiscal year ended in December, the company reported spending $163 million on R&D, whichThe Nikkei reported was double the amount 5 years earlier. The company told the publication that moving forward, it will budget the equivalent of more than 20% of group sales to capital spending and funnel the majority of that money to branded drugs.

The new facility in China is expected to be completed by 2026. Hanmi says it has about 28 new drug candidates in the pipeline at this time.

Featured Posts
Recent Posts
Archive
Search By Tags

About Pharmanaming.com and GNN

The Global Naming Network (GNN), headquartered in Geneva, is the world's largest network of independent naming and brand identity agencies.

 

With around 240 cooperating naming and branding specialists in 16  countries, from Beijing to New York and from Seoul to Paris, GNN works for clients ranging from large multinationals to small startups all over the world.

Pharmaceutical projects are coordinated from the GNN office in Amsterdam by the pharma naming specialists of Globrands.

The www.pharmanaming.com website is dedicated to our expertise and work for the health & pharma industry.

 

Please contact us for more information.

20

offices in 16 countries

240

creatives, strategists & consultants

GNN offices

China                     South Korea

France                   Italy
Germany               Japan

Netherlands          UK

India                      Singapore

Spain                     Canada

Switzerland          Russia

USA                       Dubai

5000

projects successfully executed

Pages

home                           name to brand

health & pharma        people

regulatory                   test & submit

India                             FDA

work                             blog

clients                          contact

20000

linguistic professionals worldwide

Globrands the name behind the brands

© 2020 by Globrands consultancy group

Herengracht 122, 1015 BT Amsterdam, the Netherlands

call +31206238555 or mail to pharma@globrands.com  

 

  • White LinkedIn Icon